What is MOTS-c?
MOTS-c is a 16-amino acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene. This makes it unusual: most peptides are encoded in nuclear DNA, but MOTS-c is one of a small class of mitochondria-derived peptides (MDPs) that are synthesized within mitochondria and can be secreted into the bloodstream to act as hormones.
First identified in 2015 by researchers at the USC Davis School of Gerontology, MOTS-c was found to regulate glucose metabolism, fat burning, and cellular stress responses. It has since attracted intense interest in the longevity and metabolic research communities.
How MOTS-c Works
MOTS-c acts through several interconnected pathways:
- AMPK activation: Stimulates AMP-activated protein kinase, the master metabolic switch that promotes energy efficiency
- Glucose regulation: Inhibits the folate cycle and de novo purine synthesis, which reduces insulin resistance
- Mitochondrial biogenesis: Supports mitochondrial function and number
- Exercise mimicry: Blood levels of MOTS-c rise during physical exercise, and supplementation in animal models mimics some exercise benefits
- Stress response: Acts as a mitokine — a signal sent from stressed mitochondria to coordinate whole-body responses
Research Summary
Metabolic Effects
The landmark 2015 Cell Metabolism study found that MOTS-c injection in mice reversed high-fat diet-induced obesity and insulin resistance. Treated mice showed significant improvements in blood glucose, fat metabolism, and exercise tolerance.
Longevity and Aging
A 2021 Nature Communications study found that MOTS-c levels naturally decline with age in both humans and mice. Exogenous MOTS-c treatment in aged mice improved muscle function and reduced frailty markers. Higher circulating MOTS-c in centenarians suggests it may be associated with healthy extreme longevity.
Exercise and Performance
MOTS-c is now recognized as an “exercise factor” — a peptide released during physical activity that contributes to metabolic adaptations. This has generated interest in both athletic performance and therapeutic applications for sedentary populations.
Safety Considerations
- Endogenous origin suggests potentially favorable safety compared to entirely synthetic compounds
- No human clinical safety studies published as of 2026
- Animal toxicology studies show no adverse effects at study doses
- Very early stage of clinical development
Medical Disclaimer: MOTS-c is not approved by the FDA for human use. This information is for educational purposes only. Do not use peptides without consulting a licensed healthcare provider.
Legal & Regulatory Status
MOTS-c has no FDA approval or IND status for therapeutic use. It is available from research peptide suppliers but has no established legal pathway for clinical use in the United States. Given its endogenous origin and the emerging research landscape, it may be a candidate for future clinical development.
Related Reading
- MOTS-c and KPV: Longevity Peptides in Research — Full research overview of MOTS-c as a mitochondrial peptide and exercise factor
- Anti-Aging Peptides: What the Research Actually Shows — MOTS-c in the broader landscape of longevity peptide candidates
- Peptide Pipeline: Clinical Trials to Watch in 2026 — MOTS-c analog CB5945 Phase 1 IND and other upcoming longevity peptide trials
- Peptide Therapy for Aging and Sarcopenia — Metabolic peptides and their role in age-related muscle and metabolic decline
Safety Profile Summary
MOTS-c has a favorable safety profile in animal studies with no observed toxicity. Human clinical trials are very limited as of 2026. It is an endogenous peptide naturally produced by the body, which suggests a potentially favorable safety profile, but exogenous dosing has not been rigorously evaluated in humans.
References & Further Reading
- 1. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015;21(3):443-54. [PubMed ↗]
- 2. Kim SJ, et al. Mitochondria-Derived Peptides as Novel Regulators of Metabolism. J Physiol. 2017;595(21):6613-6621. [PubMed ↗]
- 3. Reynolds JC, et al. MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis. Nat Commun. 2021;12(1):470. [PubMed ↗]
- 4. Zhai D, et al. MOTS-c Peptide Increases Survival and Decreases Bacterial Load in Mice Infected with MRSA. Mol Immunol. 2017;92:151-160. [PubMed ↗]